The global anti-inflammatory therapeutics market size accounted for US$ 99.6 billion in 2021 and is projected to reach around USD 127.5 billion by 2030, growing at a CAGR of 4.5% from 2022 to 2030.
Report Summary
The global anti-inflammatory therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the anti-inflammatory therapeutics market across the globe.
A comprehensive estimate on the anti-inflammatory therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of anti-inflammatory therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.
Anti-Inflammatory Therapeutics Market Scope
| Report Coverage | Details |
| Market Size in 2022 | USD 102.37 Billion |
| Market Size by 2030 | USD 127.5 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.5% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Class, Indication, Application, Distribution Channel, and Geography |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized anti-inflammatory therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Industrial IoT Market Size Analysis 2022 To 2030
Anti-Inflammatory Therapeutics Market Players
The report includes the profiles of key anti-inflammatory therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area are Eli Lily and Company, AstraZeneca PLC, Amgen Inc., F. Hoffman, Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, Pfizer, Inc., La Roche AG, Ferring Pharmaceuticals, Bioventus, Zimmer Biomet Holdings, Inc., Flexion Therapeutics, Inc
Market Segmentation
By Drug Class
- Anti-inflammatory Biologics
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Corticosteroids
By Indication
- Arthritis
- Rheumatoid Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Gout
- Respiratory diseases
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Crohn’s Disease
- Ulcerative Colitis
- Other inflammatory diseases
By Application
- Autoimmune
- Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
- Respiratory Diseases
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Anti-Inflammatory Therapeutics Market
5.1. COVID-19 Landscape: Anti-Inflammatory Therapeutics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Anti-Inflammatory Therapeutics Market, By Drug Class
8.1. Anti-Inflammatory Therapeutics Market, by Drug Class, 2022-2030
8.1.1. Anti-inflammatory Biologics
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Corticosteroids
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Anti-Inflammatory Therapeutics Market, By Indication
9.1. Anti-Inflammatory Therapeutics Market, by Indication, 2022-2030
9.1.1. Arthritis
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Respiratory diseases
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Multiple sclerosis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Psoriasis
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Inflammatory bowel disease
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Other inflammatory diseases
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Anti-Inflammatory Therapeutics Market, By Application
10.1. Anti-Inflammatory Therapeutics Market, by Application, 2022-2030
10.1.1. Autoimmune
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Inflammatory Diseases (Rheumatoid Arthritis Psoriasis)
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Respiratory Diseases
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Anti-Inflammatory Therapeutics Market, By Distribution Channel
11.1. Anti-Inflammatory Therapeutics Market, by Distribution Channel, 2022-2030
11.1.1. Hospital Pharmacy
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Retail Pharmacy
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Anti-Inflammatory Therapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Drug Class (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Indication (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Eli Lily and Company
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AstraZeneca PLC
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Amgen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffman
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Abbvie, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. GlaxoSmithKline
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & CO., Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Novartis
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Pfizer, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2229
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com